Literature DB >> 8510387

Hemodialysis vascular access morbidity in the United States.

H I Feldman1, P J Held, J T Hutchinson, E Stoiber, M F Hartigan, J A Berlin.   

Abstract

Extensive morbidity related to hemodialysis vascular access exists among end-stage renal disease (ESRD) patients, but the risk factors for this morbidity have not been extensively studied. Medicare ESRD patient data were obtained from 1984, 1985, and 1986. Hospitalization for vascular access morbidity (ICD-996.1, 996.6, or 996.7) was analyzed among prevalent patients and, using survival analysis, among incident patients to assess sex, age, race, and underlying cause of renal failure as risk factors. We found that 15 to 16% of hospital stays among prevalent ESRD patients were associated with vascular access-related morbidity. Black race, older age, female sex, and diabetes mellitus as a cause of kidney failure were all independent risk factors for access-related morbidity. The rate ratio comparing Blacks to Whites was 1.12 (95% C.I., 1.09, 1.16); > 64 years to 20 to 44 years, 1.53 (1.46, 1.59); men to women, 0.81 (0.79, 0.84); and diabetes to glomerulonephritis, 1.29 (1.24, 1.35). We conclude that hemodialysis vascular access malfunction causes much hospitalization among ESRD patients. Women, Blacks, the elderly, and diabetics appear to be at particularly high risk, and additional studies are needed to understand these patterns.

Entities:  

Mesh:

Year:  1993        PMID: 8510387     DOI: 10.1038/ki.1993.153

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  36 in total

1.  In vivo nanoparticle assessment of pathological endothelium predicts the development of inflow stenosis in murine arteriovenous fistula.

Authors:  Jie Cui; Chase W Kessinger; Jason R McCarthy; David E Sosnovik; Peter Libby; Ravi I Thadhani; Farouc A Jaffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

2.  K/DOQI Guidelines: What Should an Interventionalist Know?

Authors:  Aalpen A Patel; Catherine M Tuite; Scott O Trerotola
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

Review 3.  Preserving function and long-term patency of dialysis access.

Authors:  J A Akoh; N S Hakim
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

4.  Fistula First Initiative: Historical Impact on Vascular Access Practice Patterns and Influence on Future Vascular Access Care.

Authors:  Timmy Lee
Journal:  Cardiovasc Eng Technol       Date:  2017-07-10       Impact factor: 2.495

5.  Outcomes of initial hemodialysis vascular access in patients initiating dialysis with a tunneled catheter.

Authors:  Timothy Copeland; Peter Lawrence; Karen Woo
Journal:  J Vasc Surg       Date:  2019-05-27       Impact factor: 4.268

Review 6.  Genetic causation of neointimal hyperplasia in hemodialysis vascular access dysfunction.

Authors:  Timmy Lee; Davinder Wadehra
Journal:  Semin Dial       Date:  2011-09-15       Impact factor: 3.455

7.  Risk factors associated with inadequate veins for placement of arteriovenous fistulas for hemodialysis.

Authors:  Yuichi Sato; Masahito Miyamoto; Shina Sueki; Tsutomu Sakurada; Kenjiro Kimura; Ryuto Nakazawa; Maki Yoshioka; Hideo Sasaki; Satetsu Miyano; Tatsuya Chikaraishi
Journal:  J Artif Organs       Date:  2013-09-11       Impact factor: 1.731

Review 8.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

9.  Cumulative patency of contemporary fistulas versus grafts (2000-2010).

Authors:  Charmaine E Lok; Jessica M Sontrop; George Tomlinson; Dheeraj Rajan; Mark Cattral; George Oreopoulos; Jeremy Harris; Louise Moist
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

10.  Endovascular Declotting of Wall-Adherent Thrombi in Hemodialysis Vascular Access.

Authors:  Chih-Wei Hung; Chao-Lun Lai; Mu-Yang Hsieh; Ruei-Cheng Kuo; Kuei-Chin Tsai; Lin Lin; Chih-Cheng Wu
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.